SG Americas Securities LLC Acquires 59,500 Shares of Twist Bioscience Corporation $TWST

SG Americas Securities LLC lifted its holdings in Twist Bioscience Corporation (NASDAQ:TWST) by 350.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 76,484 shares of the company’s stock after acquiring an additional 59,500 shares during the quarter. SG Americas Securities LLC owned 0.13% of Twist Bioscience worth $2,426,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Campbell & CO Investment Adviser LLC raised its position in Twist Bioscience by 227.6% in the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 47,200 shares of the company’s stock worth $1,328,000 after purchasing an additional 32,792 shares during the period. Thrivent Financial for Lutherans boosted its position in Twist Bioscience by 14.5% during the third quarter. Thrivent Financial for Lutherans now owns 1,463,085 shares of the company’s stock valued at $41,171,000 after buying an additional 184,726 shares during the period. Baillie Gifford & Co. grew its stake in shares of Twist Bioscience by 62.8% during the third quarter. Baillie Gifford & Co. now owns 1,262,739 shares of the company’s stock valued at $35,533,000 after buying an additional 487,052 shares during the last quarter. EdgePoint Investment Group Inc. increased its holdings in shares of Twist Bioscience by 71.1% in the third quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock worth $114,876,000 after buying an additional 1,696,377 shares during the period. Finally, William Blair Investment Management LLC increased its holdings in shares of Twist Bioscience by 6.0% in the third quarter. William Blair Investment Management LLC now owns 4,142,283 shares of the company’s stock worth $116,564,000 after buying an additional 235,679 shares during the period.

Twist Bioscience Stock Performance

TWST opened at $50.21 on Friday. The business has a 50 day simple moving average of $46.99 and a two-hundred day simple moving average of $37.36. The firm has a market capitalization of $3.08 billion, a price-to-earnings ratio of -39.23 and a beta of 2.20. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $57.88.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The business had revenue of $103.70 million during the quarter, compared to the consensus estimate of $100.32 million. The company’s quarterly revenue was up 16.9% on a year-over-year basis. Analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insiders Place Their Bets

In other Twist Bioscience news, CEO Emily M. Leproust sold 2,423 shares of the business’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $46.43, for a total transaction of $112,499.89. Following the transaction, the chief executive officer directly owned 860,629 shares of the company’s stock, valued at approximately $39,959,004.47. The trade was a 0.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Melissa A. Starovasnik sold 1,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $51.00, for a total transaction of $51,000.00. Following the completion of the transaction, the director owned 25,722 shares of the company’s stock, valued at $1,311,822. This trade represents a 3.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 49,190 shares of company stock valued at $2,285,695 over the last quarter. 3.08% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Robert W. Baird set a $50.00 target price on Twist Bioscience in a report on Tuesday, February 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Friday, March 27th. Evercore increased their price objective on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a research note on Tuesday, February 3rd. Guggenheim raised their target price on shares of Twist Bioscience from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Finally, TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $46.50.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.